欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

未开盘 01-22 16:08:18

6.990

-0.280

-3.85%

最高7.250	最低6.920	成交量226.35万
今开7.180	昨收7.270	日振幅4.54%
总市值56.97亿	流通市值56.97亿	总股本8.15亿
成交额1,600万	换手率0.28%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":6.99,"timestamp":1769069298005,"preClose":7.27,"halted":0,"volume":2263500,"delay":0,"changeRate":-0.03851444291609345,"floatShares":815000000,"shares":815000000,"eps":-0.392324,"marketStatus":"未开盘","change":-0.28,"latestTime":"01-22 16:08:18","open":7.18,"high":7.25,"low":6.92,"amount":15997055,"amplitude":0.045392,"askPrice":6.99,"askSize":5000,"bidPrice":6.91,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.335,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769131800000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":7.27,"openAndCloseTimeList":[[1769045400000,1769054400000],[1769058000000,1769068800000]],"volumeRatio":1.4498288131116037,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2605462938","title":"杭州邦顺制药股份有限公司-B向港交所提交上市申请书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462938","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462938?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:55","pubTimestamp":1769075700,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月22日，港交所文件显示，杭州邦顺制药股份有限公司-B向港交所提交上市申请书，独家保荐人为中信建投国际。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-22/doc-inhiepsr4621818.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-22/doc-inhiepsr4621818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191","HEXmain"],"gpt_icon":0},{"id":"2605546621","title":"中信建投：中国医药产业正站在全球化价值重估起点 看好相关创新药及制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2605546621","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605546621?lang=zh_cn&edition=full","pubTime":"2026-01-22 16:30","pubTimestamp":1769070647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，国内医药企业国际化竞争力持续提升，新技术推动行业快速发展，国家政策鼓励创新药发展，看好相关创新药及制药企业。整体看，中国医药产业正站在全球化价值重估的起点，2026年将成为验证转型成效的关键节点。中国药企呈现全球化提速的格局。中国CXO企业凭借ADC、双抗、GLP-1等领域的一站式服务平台能力，完成从“中间供应商”到“全球创新赋能者”的跃升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06978","01477","BK0082","BK0250","BK1161","BK1574","601066","BK1191","BK0028","600056","BK0185","BK0188","BK0175","BK0276","BK0010"],"gpt_icon":0},{"id":"2605808455","title":"中邮证券：医药行业AI制药从降本增效到分子创新 数据生产构筑长期壁垒","url":"https://stock-news.laohu8.com/highlight/detail?id=2605808455","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605808455?lang=zh_cn&edition=full","pubTime":"2026-01-22 10:41","pubTimestamp":1769049675,"startTime":"0","endTime":"0","summary":"投资思路上来看，该行认为在于理解当下AI在制药中的作用地位、商业模式和成长空间、行业成长的关键要素和竞争壁垒。中邮证券主要观点如下：AI在制药中的作用是什么？AI在制药端最成熟的落地应用在于提升了临床前的降本增效：AI虚拟筛选极大地降低了真实试验中所需要投入的化合物的数量，从而有效缩短了临床前研发周期、大幅减少研发成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","161027","BK1574","BK1191"],"gpt_icon":0},{"id":"2605458029","title":"带动物流配送链条 广东保厘制药40亿片制剂项目动工建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2605458029","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605458029?lang=zh_cn&edition=full","pubTime":"2026-01-22 10:03","pubTimestamp":1769047380,"startTime":"0","endTime":"0","summary":"转自：中国交通新闻网近日，广东保厘制药年产40亿片（粒）制剂项目在江门开平市沙塘镇正式动工。该项目位于广东省江门开平市沙塘镇，由中交第四航务工程局有限公司承建，规划建设生产配套用房、行政配套用房及室外配套设施三大板块，涵盖联合厂房、综合制剂车间、青霉素车间、危险品库等核心功能区。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-22/doc-inhicwux4738258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2605177111","title":"CORVUS制药盘前跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605177111","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605177111?lang=zh_cn&edition=full","pubTime":"2026-01-21 17:15","pubTimestamp":1768986958,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2605106986","title":"每日卖空追踪 | 欧康维视生物-B 01月21日卖空量成交2.25万股，卖空比例为1.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605106986","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605106986?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:30","pubTimestamp":1768984223,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间01月21日，跌1.09%，卖空量成交2.25万股，较上一交易日减少66.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121165248a444d235&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121165248a444d235&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2605910693","title":"欧康维视生物-B01月21日遭主力抛售26.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605910693","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605910693?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:15","pubTimestamp":1768983351,"startTime":"0","endTime":"0","summary":"01月21日, 欧康维视生物-B股价跌1.09%，报收7.27元，成交金额1550.8万元，换手率0.26%，振幅3.27%，量比1.69。欧康维视生物-B今日主力资金净流出26.3万元，连续5日净流出，上一交易日主力净流出30.5万元。该股近5个交易日下跌8.31%，主力资金累计净流出415.2万元；近20日主力资金累计净流出88.6万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121163245a69b6d4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121163245a69b6d4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2605112491","title":"港股异动 | 森松国际(02155)再涨超6% 国内外制药产能进入扩张周期 公司新签订单快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2605112491","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605112491?lang=zh_cn&edition=full","pubTime":"2026-01-21 11:36","pubTimestamp":1768966604,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，森松国际再涨超6%，截至发稿，涨5.24%，报11.04港元，成交额2164.01万港元。该行指出，公司下游行业景气度高，制药行业进入复苏周期，海外MNC的CAPEX需求恢复，新签订单快速增长，叠加公司海外生产基地产能释放，工程周期有望缩短，超百亿的在手订单加速交付，驱动业绩高速增长。森松模块化数据中心业务优势显著，能够高效交付，满足算力刚需。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02800","BK1183","02155","01477","BK1587","BK1574","BK1191","LU1171460220.USD","BK1548","BK1610"],"gpt_icon":0},{"id":"2604019955","title":"歌礼制药-B(01672)：歌礼选定新一代每月一次皮下注射GLP-1R/GIPR/GCGR 三靶点激动剂多肽ASC37进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2604019955","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604019955?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:54","pubTimestamp":1768902869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，董事会宣布其已选定新一代每月一次皮下给药的 GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37注射剂作为临床开发候选药物。体外实验显示，在对GLP-1R、GIPR和GCGR的激动活性方面，ASC37比 retatrutide平均分别强约5倍、4倍和4倍。歌礼计划将GLP-1R/ GIPR/GCGR三靶点激动剂多肽ASC37与其每月一次皮下给药的胰淀素受体激动剂多肽ASC36联用，治疗肥胖症、糖尿病以及其它代谢疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4160","01477","BK1191","BK1574","01672","BK4590","GLP","GIPR","BK1161","BK4144"],"gpt_icon":0},{"id":"2604619955","title":"拓新药业最新公告：子公司新乡制药通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2604619955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604619955?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:49","pubTimestamp":1768902594,"startTime":"0","endTime":"0","summary":"拓新药业公告称，全资子公司新乡制药股份有限公司近日收到河南省药品监督管理局核发的两份《药品GMP符合性检查告知书》，涉及原料药和原料药的生产车间及生产线。此次通过检查标志着公司相应生产设施与管理体系满足药品生产质量管理规范要求，其中原料药即可上市销售，原料药待通过国家药品监督管理局备案后也可上市销售。但需注意，药品行业受多重因素影响，相关药品的生产组织、市场销售等后续经营情况存在一定不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000028689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","301089","01477","BK1574"],"gpt_icon":0},{"id":"2604716327","title":"港股异动 | 歌礼制药-B(01672)午前拉升逾5% ASC30竞争优势显著 机构称其BD潜力较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2604716327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604716327?lang=zh_cn&edition=full","pubTime":"2026-01-20 11:48","pubTimestamp":1768880925,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672)午前拉升逾5%，截至发稿，涨5.12%，报13.56港元，成交额1328.47万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260120/20260120114859_81968.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260120/20260120114859_81968.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01477","BK1161","BK1191","BK1515","01672","BK1574"],"gpt_icon":0},{"id":"2604592291","title":"英硅智能(03696)与衡泰生物达成逾5亿港币合作 AI制药走向多方协同与商业化考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2604592291","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604592291?lang=zh_cn&edition=full","pubTime":"2026-01-20 08:04","pubTimestamp":1768867444,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，刚于 2025 年底登陆港交所的AI制药头部企业英硅智能再传捷报，继在 2026 年迎来BD“开门红”后，公司本周宣布与深圳衡泰生物签署一项总额逾 5 亿港币的研发合作协议，共同开发协议，围绕其神经科学创新药物 ISM8969 展开全球开发合作，探索包括帕金森病在内的中枢神经系统适应症。根据协议条款，双方各持有该项目50%全球权益，英硅智能将主导 ISM8969 的 IND 申报及 I 期临床试验，随后由衡泰生物负责后续临床开发、监管申报及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191","03696"],"gpt_icon":0},{"id":"2604615931","title":"欧康维视生物-B(01477)：OT-703于海南博鳌进行的真实世界研究完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2604615931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604615931?lang=zh_cn&edition=full","pubTime":"2026-01-20 07:30","pubTimestamp":1768865436,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，本集团产品OT-703最近已完成于中华人民共和国海南省博鳌乐城国际医疗旅游先行区进行的真实世界研究合共195例患者的入组。其已获得美国食品药品监督管理局 的监管批准，并以商号“ILUVIEN”上市。OT-703是FDA批准的唯一一款缓释长达3年的治疗DME的皮质类固醇眼内植入剂。于2023年12月，OT-703获得香港药剂业及毒药管理局的批准，可根据香港法例第 138章《药剂业及毒药条例》在香港注册为医药产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1394801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2604184090","title":"每日卖空追踪 | 歌礼制药-B 01月19日卖空量成交15.6万股，卖空比例为13.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604184090","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604184090?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:30","pubTimestamp":1768811423,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间01月19日，跌3.59%，卖空量成交15.6万股，较上一交易日减少65.41%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119163948a43c242d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119163948a43c242d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","BK1515","BK1574","01672","01477"],"gpt_icon":0},{"id":"2604840521","title":"歌礼制药-B01月19日遭主力抛售18.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604840521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604840521?lang=zh_cn&edition=full","pubTime":"2026-01-19 16:15","pubTimestamp":1768810513,"startTime":"0","endTime":"0","summary":"01月19日, 歌礼制药-B股价跌3.59%，报收12.90元，成交金额1484.5万元，换手率0.12%，振幅3.06%，量比0.41。歌礼制药-B今日主力资金净流出18.2万元，上一交易日主力净流出269.9万元。该股近5个交易日上涨3.69%，主力资金累计净流入130.8万元；近20日主力资金累计净流入71.4万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119161617a43c07fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119161617a43c07fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01672","01477","BK1574","BK1515","BK1191"],"gpt_icon":0},{"id":"2604913246","title":"欧康维视生物-B盘中异动 股价大跌5.61%报7.060港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604913246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604913246?lang=zh_cn&edition=full","pubTime":"2026-01-19 10:52","pubTimestamp":1768791155,"startTime":"0","endTime":"0","summary":"2026年01月19日早盘10时52分，欧康维视生物-B股票出现波动，股价急速跳水5.61%。截至发稿，该股报7.060港元/股，成交量48.9285万股，换手率0.06%，振幅6.02%。资金方面，该股资金流入44.144万港元，流出294.932万港元。欧康维视生物-B股票所在的生物技术行业中，整体跌幅为3.70%。欧康维视生物-B公司简介：欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119105235953d468f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119105235953d468f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大会诺华、阿斯利康、辉瑞等巨头超百亿美元交易频现，中国资产成最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603937939?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","02268","01477","BK1191","ZLAB","01530","09688","BK1574","02615","06978","02359","BK1161","02269","AAPG"],"gpt_icon":0},{"id":"2603607259","title":"富士莱：目前暂无AI在制药领域的业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2603607259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603607259?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:48","pubTimestamp":1768481302,"startTime":"0","endTime":"0","summary":"证券之星消息，富士莱(301258)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：以“AI+发酵+合成生物学”的落地应用，践行AI4S核心逻辑（数据与模型驱动科研生产，提升效率、缩短周期），属于AI4S在生物医药制造领域的典型产业应用案例公司有这方便的运用吗？富士莱回复：尊敬的投资者，您好！公司密切关注AI在制药领域的应用和发展，目前暂无相关业务布局。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500038639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301258","BK1574","BK1191","BK0239","01477"],"gpt_icon":0},{"id":"2603567077","title":"石药创新制药股份有限公司2025年度业绩预亏，研发投入加大及收购影响利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2603567077","media":"中金财经","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603567077?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:56","pubTimestamp":1768467375,"startTime":"0","endTime":"0","summary":"中访网数据 石药创新制药股份有限公司于2026年1月15日发布2025年度业绩预告。预告显示，公司预计2025年度归属于上市公司股东的净利润将出现亏损，亏损额在17,000万元至25,500万元之间，较上年同期的盈利5,372.63万元大幅下滑。其次，公司于2025年11月初完成了对控股子公司巨石生物制药有限公司29%少数股权的收购，持股比例提升至80%。　　公司表示，此次业绩预告数据未经审计，具体财务数据将以2025年年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260115/31945252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU0072913022.USD","HK0000165453.HKD","LU0067412154.USD","BK1574","LU0326950275.SGD","LU0880133367.SGD","LU1328277881.USD","LU1226287529.USD","LU0501845795.SGD","LU1807302812.USD","IE00B543WZ88.USD","LU2039709279.SGD","01093","LU1951186391.HKD","IE00BZ08YR35.GBP","IE0008369823.USD","LU1993786604.SGD","IE0008368742.USD","LU1813983027.USD","01477","LU1226288170.HKD","IE00BZ08YT58.USD","SG9999004220.SGD","LU1152091754.HKD","LU1008478684.HKD","LU1226288253.USD","IE00BZ08YS42.EUR","BK1521","LU1226287875.USD","IE00B5MMRT66.SGD","BK1191","LU0315179316.USD","BK1515","LU1152091168.USD","LU0140636845.USD","IE00B031HY20.USD","LU1960683339.HKD","LU0314109678.HKD","LU1226287792.SGD"],"gpt_icon":0},{"id":"2603603390","title":"每日卖空追踪 | 歌礼制药-B 01月15日卖空量成交17.7万股，卖空比例为4.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603390?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:30","pubTimestamp":1768465823,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间01月15日，涨2.44%，卖空量成交17.7万股，较上一交易日减少59.4%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115164024a71dc75e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115164024a71dc75e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1161","BK1191","01477","01672"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.1004},{"period":"1month","weight":-0.1152},{"period":"3month","weight":-0.1629},{"period":"6month","weight":-0.2548},{"period":"1year","weight":0.7259},{"period":"ytd","weight":-0.0554}],"compareEarnings":[{"period":"1week","weight":-0.0109},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.018},{"period":"6month","weight":0.0489},{"period":"1year","weight":0.3464},{"period":"ytd","weight":0.039}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.106707},{"month":2,"riseRate":0.4,"avgChangeRate":-0.049128},{"month":3,"riseRate":0.6,"avgChangeRate":0.058111},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}